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Purpose: To document the types of evidence and value considered by European health technology 
assessment agencies when making recommendations about antibiotics. 
Methods: We studied five antibiotics that have gone through a health technology assessment 
process in at least one European country since 2010: fidaxomicin, aztreonam, ceftaroline fosamil, 
tigecycline, and colistimethate sodium. We selected the drugs to include a mix of new technologies 
and reformulations of older products. For each antibiotic, we identified every report from a health 
technology assessment body publicly available in English, Spanish, German, or Dutch. We 
systematically reviewed the reports to identify the evidence, sources of value, and other factors the 
agency considered in the health technology assessment. We supplemented this review by 
interviewing the pharmaceutical companies that developed the products to collect additional 
information about the health technology assessment process and its data and modelling 
requirements. 
Results: We found health technology assessments from at least three countries for each product. 
Fidaxomicin was the most widely studied product with reports available from seven countries. The 
health technology assessments are based on clinical trial data and simple economic models that 
focus primarily on the direct treatment benefit of the drugs to patients. The threat of antibiotic 
resistance was mentioned irregularly. The assessments did not consider the value of antibiotics in 
enabling surgeries and other procedures, the insurance value of having an approved antibiotic ready 
when a new resistant outbreak emerges, or the diversity value of having multiple drugs with 
different modes of action available for a given infection. 
Conclusions: Current health technology assessment practices do not encapsulate the full value of 
antibiotics. Ignoring the types of value unique to antibiotics may result in their being undervalued, 
which could make it less enticing for pharmaceutical companies to invest in research and 
development of new antibiotic products. There is a need for simple modelling frameworks that can 
better capture the true economic value of antibiotics. 
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